All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129

Dan Douer; Lynette N. Zickl; Charles A. Schiffer; Fredrick R. Appelbaum; James H. Feusner; Lois Shepherd; Cheryl L. Willman; Clara D. Bloomfield; Elisabeth Paietta; Robert E. Gallagher; Jae H. Park; Jacob M. Rowe; Peter H. Wiernik; Martin S. Tallman

doi:10.1016/j.leukres.2013.03.001

All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129

Dan Douer^*, Lynette N. Zickl, Charles A. Schiffer, Fredrick R. Appelbaum, James H. Feusner, Lois Shepherd, Cheryl L. Willman, Clara D. Bloomfield, Elisabeth Paietta, Robert E. Gallagher, Jae H. Park, Jacob M. Rowe, Peter H. Wiernik, Martin S. Tallman

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

We report a long-term follow-up (median 11.8 years) of the First North American Intergroup Study. 379 patients were randomized to induction with ATRA or to chemotherapy. All complete responders (CR) received consolidation chemotherapy, then randomized to 1 year ATRA or observation. 245 patients received ATRA sometime during the study: 195 (80%) achieved a CR. Nine (4.6%) relapsed late (>3 years from CR), the last occurred after 4.6 years; 7 of them were still alive after 5.5-15 years. In APL patients, late relapses are uncommon, and those who sustain CR >5 years can be considered cured.

Original language	English (US)
Pages (from-to)	795-801
Number of pages	7
Journal	Leukemia Research
Volume	37
Issue number	7
DOIs	https://doi.org/10.1016/j.leukres.2013.03.001
State	Published - Jul 2013

Funding

This study was coordinated by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Health Service Grants CA21115, CA23318, CA66636, CA17145, CA14958, CA77658, CA32102, CA 37027, CA12213 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. Research support for the study: CA021115 and CA114737 were awarded to EP and CA56771 to REG.

Keywords

Acute promyelocytic leukemia
All-trans retinoic acid
Late relapse

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2013.03.001

Cite this

Douer, D., Zickl, L. N., Schiffer, C. A., Appelbaum, F. R., Feusner, J. H., Shepherd, L., Willman, C. L., Bloomfield, C. D., Paietta, E., Gallagher, R. E., Park, J. H., Rowe, J. M., Wiernik, P. H., & Tallman, M. S. (2013). All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129. Leukemia Research, 37(7), 795-801. https://doi.org/10.1016/j.leukres.2013.03.001

@article{aefc18af8027470fb6e86f30e6fb167f,

title = "All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129",

abstract = "We report a long-term follow-up (median 11.8 years) of the First North American Intergroup Study. 379 patients were randomized to induction with ATRA or to chemotherapy. All complete responders (CR) received consolidation chemotherapy, then randomized to 1 year ATRA or observation. 245 patients received ATRA sometime during the study: 195 (80%) achieved a CR. Nine (4.6%) relapsed late (>3 years from CR), the last occurred after 4.6 years; 7 of them were still alive after 5.5-15 years. In APL patients, late relapses are uncommon, and those who sustain CR >5 years can be considered cured.",

keywords = "Acute promyelocytic leukemia, All-trans retinoic acid, Late relapse",

author = "Dan Douer and Zickl, {Lynette N.} and Schiffer, {Charles A.} and Appelbaum, {Fredrick R.} and Feusner, {James H.} and Lois Shepherd and Willman, {Cheryl L.} and Bloomfield, {Clara D.} and Elisabeth Paietta and Gallagher, {Robert E.} and Park, {Jae H.} and Rowe, {Jacob M.} and Wiernik, {Peter H.} and Tallman, {Martin S.}",

note = "Funding Information: This study was coordinated by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Health Service Grants CA21115, CA23318, CA66636, CA17145, CA14958, CA77658, CA32102, CA 37027, CA12213 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. Research support for the study: CA021115 and CA114737 were awarded to EP and CA56771 to REG. ",

year = "2013",

month = jul,

doi = "10.1016/j.leukres.2013.03.001",

language = "English (US)",

volume = "37",

pages = "795--801",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "7",

}

Douer, D, Zickl, LN, Schiffer, CA, Appelbaum, FR, Feusner, JH, Shepherd, L, Willman, CL, Bloomfield, CD, Paietta, E, Gallagher, RE, Park, JH, Rowe, JM, Wiernik, PH & Tallman, MS 2013, 'All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129', Leukemia Research, vol. 37, no. 7, pp. 795-801. https://doi.org/10.1016/j.leukres.2013.03.001

TY - JOUR

T1 - All-trans retinoic acid and late relapses in acute promyelocytic leukemia

T2 - Very long-term follow-up of the North American Intergroup Study I0129

AU - Douer, Dan

AU - Zickl, Lynette N.

AU - Schiffer, Charles A.

AU - Appelbaum, Fredrick R.

AU - Feusner, James H.

AU - Shepherd, Lois

AU - Willman, Cheryl L.

AU - Bloomfield, Clara D.

AU - Paietta, Elisabeth

AU - Gallagher, Robert E.

AU - Park, Jae H.

AU - Rowe, Jacob M.

AU - Wiernik, Peter H.

AU - Tallman, Martin S.

N1 - Funding Information: This study was coordinated by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Health Service Grants CA21115, CA23318, CA66636, CA17145, CA14958, CA77658, CA32102, CA 37027, CA12213 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. Research support for the study: CA021115 and CA114737 were awarded to EP and CA56771 to REG.

PY - 2013/7

Y1 - 2013/7

N2 - We report a long-term follow-up (median 11.8 years) of the First North American Intergroup Study. 379 patients were randomized to induction with ATRA or to chemotherapy. All complete responders (CR) received consolidation chemotherapy, then randomized to 1 year ATRA or observation. 245 patients received ATRA sometime during the study: 195 (80%) achieved a CR. Nine (4.6%) relapsed late (>3 years from CR), the last occurred after 4.6 years; 7 of them were still alive after 5.5-15 years. In APL patients, late relapses are uncommon, and those who sustain CR >5 years can be considered cured.

AB - We report a long-term follow-up (median 11.8 years) of the First North American Intergroup Study. 379 patients were randomized to induction with ATRA or to chemotherapy. All complete responders (CR) received consolidation chemotherapy, then randomized to 1 year ATRA or observation. 245 patients received ATRA sometime during the study: 195 (80%) achieved a CR. Nine (4.6%) relapsed late (>3 years from CR), the last occurred after 4.6 years; 7 of them were still alive after 5.5-15 years. In APL patients, late relapses are uncommon, and those who sustain CR >5 years can be considered cured.

KW - Acute promyelocytic leukemia

KW - All-trans retinoic acid

KW - Late relapse

UR - http://www.scopus.com/inward/record.url?scp=84878516956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878516956&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.03.001

DO - 10.1016/j.leukres.2013.03.001

M3 - Article

C2 - 23528262

AN - SCOPUS:84878516956

SN - 0145-2126

VL - 37

SP - 795

EP - 801

JO - Leukemia Research

JF - Leukemia Research

IS - 7

ER -

All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this